The Presentation of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Is Not Influenced by the Presence or Absence of Joint Hypermobility. — CFSMEATLAS
The Presentation of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Is Not Influenced by the Presence or Absence of Joint Hypermobility.
Vogel, Sarah K, Primavera, Isabelle R, Marden, Colleen L et al. · The Journal of pediatrics · 2022 · DOI
Quick Summary
This study looked at whether people with ME/CFS who have unusually flexible joints (joint hypermobility) experience the illness differently than those without this feature. Researchers compared 55 patients and found no meaningful differences between the two groups in terms of when symptoms started, how severe they were, or how much the condition affected their daily lives. Even though joint hypermobility may increase the risk of developing ME/CFS, having it does not appear to change how the illness presents or progresses.
Why It Matters
This study clarifies an important clinical question: while joint hypermobility may predispose people to develop ME/CFS, it does not appear to create a distinct or more severe form of the illness. This helps clinicians understand that ME/CFS patients with joint hypermobility may not require fundamentally different management approaches based solely on hypermobility status.
Observed Findings
No significant difference in mean age at ME/CFS onset between hypermobility-positive and negative groups (13.3 vs 13.3 years)
No significant differences in frequency or severity of ME/CFS symptoms, orthostatic intolerance symptoms, or comorbid conditions
No significant differences in health-related quality of life measures (PedsQL, Functional Disability Inventory, Fatigue Scale, Anxiety Subscale)
Findings remained consistent using both Beighton score cutoff ≥4 and ≥5 to define hypermobility
Inferred Conclusions
Joint hypermobility, while a risk factor for developing ME/CFS, does not influence the presentation or severity of ME/CFS once established
The clinical course and quality-of-life impact of ME/CFS appear independent of hypermobility status
Joint hypermobility status alone may not warrant distinct clinical management or prognostic considerations in ME/CFS patients
Remaining Questions
What is the underlying mechanism by which joint hypermobility increases ME/CFS susceptibility if it does not modify illness presentation?
Do other connective tissue features (beyond Beighton scoring) that commonly co-occur with hypermobility influence ME/CFS presentation?
Would findings differ in adult populations or in patients with more severe ME/CFS?
What This Study Does Not Prove
This study does not prove that joint hypermobility plays no role in ME/CFS pathogenesis—only that once ME/CFS develops, hypermobility does not alter its clinical features. The small sample size (55 patients) limits generalizability. The cross-sectional design cannot establish causality or clarify the mechanism by which hypermobility increases ME/CFS risk.
Tags
Symptom:Orthostatic IntolerancePainFatigue
Phenotype:Pediatric
Method Flag:Weak Case DefinitionNo ControlsSmall Sample